等待开盘 04-02 09:30:00 美东时间
+0.040
+1.00%
今日重点评级关注:LUCID CAPITAL MARKETS:上调INmune Bio评级至"买入" 目标价从2美元升至9美元;Clear Street:维持MoonLake Immunotherapeutics Class A"买入"评级,目标价从45美元升至70美元
03-12 12:34
Banco Bradesco BBI S.A analyst Daniel Federle upgrades Vtex (NYSE:VTEX) from Neutral to Outperform and announces $5 price target.
03-11 19:03
VTEX shares are trading higher after the company reported better-than-expected ...
02-27 23:39
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据VTEX业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - Q4订阅收入:6,670万美元,同比增长12.2%(美元计价)、5.4%(汇率中性) - 全年订阅收入:2.349亿美元,同比增长7.9%(美元计价)、9.5%(汇率中性) - GMV:Q4达63亿美元,同比增长17.2%(美元计价)、10%(汇率中性);全年205亿美元,同比增长12.1%(美元计价)、12.9%(汇率中性) **盈利能力:** - Q4订阅业务毛利率:81.8%,较上年同期78.8%提升3个百分点 - Q4总毛利率:79.6%,较上年同
02-27 12:01
The Q4 earnings report for Vtex (NYSE:VTEX) was released on Thursday, February ...
02-27 05:04
Vtex (NYSE:VTEX) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.04 by 25.58 percent. This is a 54.29 percent increase over earnings of $0.04 per share from the same period
02-27 05:04
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
今日重点评级关注:Benchmark:维持TNL Mediagene"投机性买入"评级,目标价从3.5美元升至14美元;康托·菲茨杰拉德:维持Eupraxia Pharmaceuticals"超配"评级,目标价从11美元升至19美元
01-16 10:04
UBS analyst Leonardo Olmos downgrades Vtex (NYSE:VTEX) from Buy to Neutral and lowers the price target from $8 to $4.
01-15 21:11
今日重点评级关注:Guggenheim:维持InflaRx"买入"评级,目标价从10美元升至22美元;巴克莱:维持Tandem糖尿病护理"超配"评级,目标价从51美元升至55美元
2025-11-11 10:49